Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. doi: 10.1093/neuonc/noaa200.
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors (malignant and non-malignant) and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates (incidence and mortality) are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.79 (Malignant AAAIR=7.08, non-Malignant AAAIR=16.71). This rate was higher in females compared to males (26.31 versus 21.09), Blacks compared to Whites (23.88 versus 23.83), and non-Hispanics compared to Hispanics (24.23 versus 21.48). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.5% of all tumors), and the most common non-malignant tumor was meningioma (38.3% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.14. An estimated 83,830 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2020 (24,970 malignant and 58,860 non-malignant). There were 81,246 deaths attributed to malignant brain and other CNS tumors between 2013 and 2017. This represents an average annual mortality rate of 4.42. The 5-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 23.5% and for a non-malignant brain and other CNS tumor was 82.4%.
美国中央脑肿瘤注册中心(CBTRUS)与疾病控制与预防中心(CDC)和国家癌症研究所(NCI)合作,是美国最大的专注于原发性脑肿瘤和其他中枢神经系统(CNS)肿瘤的基于人群的注册中心,代表了整个美国人口。本报告包含了最新的基于人群的原发性脑肿瘤(恶性和非恶性)数据,在完整性和准确性方面超过了之前所有的 CBTRUS 报告。所有发病率(发病率和死亡率)均采用 2000 年美国标准人口进行年龄调整,并以每 10 万人为单位呈现。所有恶性和非恶性脑肿瘤和其他 CNS 肿瘤的平均年度年龄调整发病率(AAAIR)为 23.79(恶性 AAAIR=7.08,非恶性 AAAIR=16.71)。女性的发病率高于男性(26.31 比 21.09),黑人高于白人(23.88 比 23.83),非西班牙裔高于西班牙裔(24.23 比 21.48)。最常见的恶性脑肿瘤和其他 CNS 肿瘤是胶质母细胞瘤(所有肿瘤的 14.5%),最常见的非恶性肿瘤是脑膜瘤(所有肿瘤的 38.3%)。胶质母细胞瘤在男性中更常见,脑膜瘤在女性中更常见。在儿童和青少年(0-19 岁)中,所有原发性脑肿瘤和其他 CNS 肿瘤的发病率为 6.14。预计 2020 年美国将诊断出 83830 例恶性和非恶性脑肿瘤和其他 CNS 肿瘤(24970 例恶性和 58860 例非恶性)。2013 年至 2017 年期间,恶性脑肿瘤和其他 CNS 肿瘤导致 81246 人死亡。这代表了平均每年 4.42%的死亡率。恶性脑肿瘤和其他 CNS 肿瘤诊断后的 5 年相对生存率为 23.5%,非恶性脑肿瘤和其他 CNS 肿瘤为 82.4%。